var data={"title":"Insulin glargine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Insulin glargine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7861?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=insulin-glargine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Insulin glargine: Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=insulin-glargine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Insulin glargine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50707937\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Insulin Pen Safety Alert</span>\n      <span class=\"collapsible-date\">October 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Institute for Safe Medication Practices (ISMP) National Medication Errors Reporting Program (MERP) has issued a safety alert regarding reports of patients incorrectly using insulin pens at home, resulting in severe cases of hyperglycemia. Patients were not removing the inner cover of a standard insulin pen needle prior to attempting to administer the insulin, and thus were not receiving insulin doses.</p>\n        <p style=\"text-indent:0em;\">Health care professionals should instruct patients on the proper use of insulin pens and require patient demonstration to verify understanding. They should also verify which pen needles patients will be using at home, either standard pens or pens with automatic needle retraction devices, and tailor instruction accordingly.</p>\n        <p style=\"text-indent:0em;\">More information can be found at http://www.ismp.org/NAN/files/NAN-20171012.pdf.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114346\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Basaglar KwikPen;</li>\n      <li>Lantus;</li>\n      <li>Lantus SoloStar;</li>\n      <li>Toujeo SoloStar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2186124\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Basaglar;</li>\n      <li>Lantus;</li>\n      <li>Toujeo SoloStar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114349\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Insulin, Long-Acting</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2110691\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Insulin glargine is a long-acting insulin administered by SubQ injection. Insulin glargine is approximately equipotent to human insulin, but has a slower onset, no pronounced peak, and a longer duration of activity. Insulin requirements vary dramatically between patients and dictates frequent monitoring and close medical supervision.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diabetes mellitus, type 1:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Insulin glargine-specific dosing:</b> Initial dose: Approximately one-third to one-half of the total daily insulin requirement administered once daily. A rapid-acting or short-acting insulin should also be used to complete the balance (~1/2 to 2/3) of the total daily insulin requirement. Adjust dosage according to patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to insulin glargine from other insulin therapies:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Converting from once-daily NPH insulin to insulin glargine: May be substituted on an equivalent unit-per-unit basis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Converting from twice-daily NPH insulin to insulin glargine: Initial dose: Use 80% of the total daily dose of NPH (eg, 20% reduction); administer once daily; adjust dosage according to patient response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion between Toujeo, Lantus, and Basaglar: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Conversion from once-daily Toujeo to once-daily Lantus or once-daily Basaglar: Initial dose: Use 80% of the dose of Toujeo (eg, 20% reduction); adjust dosage according to patient blood glucose response.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Conversion from once-daily Lantus to once-daily Toujeo or once-daily Basaglar: Initial dose: May be substituted on an equivalent unit-per-unit basis; however, generally a higher daily dosage of Toujeo will be required to achieve the same level of glycemic control as with Lantus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General insulin dosing (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Type 1:</b> SubQ: <b>Note:</b> Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the total units/kg/day of all insulin formulations used. Insulin glargine must be used in combination with a rapid- or short-acting insulin.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Initial total insulin dose:</b> 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Usual maintenance range:</b> 0.5 to 1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Nonobese: 0.4 to 0.6 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Obese: 0.8 to 1.2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Division of daily insulin requirement (&quot;conventional therapy&quot;):</b> Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate-acting or a long-acting form of insulin (eg, insulin glargine) (in 1 to 2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, lispro, aspart, glulisine) or short-acting (regular) form of insulin.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Division of daily insulin requirement (&quot;intensive therapy&quot;):</b> Basal insulin delivery with 1 or 2 doses of intermediate-acting or long-acting insulin formulations superimposed with doses of short-acting (regular) insulin or rapid-acting insulin (eg, lispro, aspart, glulisine) formulations 3 or more times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Dosage adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diabetes mellitus, type 2:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Insulin glargine-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Manufacturer&rsquo;s labeling:</b> Initial basal insulin dose: 0.2 units/kg once daily; for Lantus or Basaglar, up to 10 units/day initially is recommended. Adjust dosage according to patient response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to insulin glargine from other insulin therapies: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Converting from once-daily NPH insulin to insulin glargine: May be substituted on an equivalent unit-per-unit basis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Converting from twice-daily NPH insulin to insulin glargine: Initial dose: Use 80% of the total daily dose of NPH (eg, 20% reduction); administer once daily; adjust dosage according to patient response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion between Toujeo, Lantus, or Basaglar: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Conversion from once-daily Toujeo to once-daily Lantus or once-daily Basaglar: Initial dose: Use 80% of the dose of Toujeo (eg, 20% reduction); adjust dosage according to patient blood glucose response.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Conversion from once-daily Lantus to once-daily Toujeo or once-daily Basaglar: Initial dose: May be substituted on an equivalent unit-per-unit basis; however, generally a higher daily dosage of Toujeo will be required to achieve the same level of glycemic control as with Lantus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Alternate recommendations (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 10 units <b>or</b> 0.1 to 0.2 units/kg once daily, usually in combination with metformin +/- other noninsulin agent (ADA 2017f). Alternatively, if HbA<sub>1c</sub> &gt;8% prior to initiation of basal insulin, 0.2 to 0.3 units/kg once daily is recommended (Garber [AACE/ACE 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">To reach fasting blood glucose target: Adjust dose by 10% to 15% <b>or</b> 2 to 4 units; may adjust at weekly or twice weekly intervals (ADA 2017f)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For hypoglycemia: If no clear reason for hypoglycemia, decrease dose by 4 units <b>or </b>by 10% to 20% (ADA 2017f)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Surgical patients:</i> On the morning of surgery or procedure, give 60% to 80% of the usual dose of long-acting analogs (eg, detemir, glargine, or degludec) (ADA 2017d)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General considerations for insulin use in type 2 diabetes (off-label): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Timing of </i>\n      <i>initiation:</i> Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3 months with lifestyle intervention and metformin monotherapy or dual therapy, respectively (unless contraindications to metformin exist). Preference is not given for which agent(s) should be added to metformin (drug choice should be individualized based on patient characteristics). If HbA1c target not achieved after ~3 months of triple therapy, consider initiating basal insulin (usually with metformin +/- other noninsulin agent) or if patient already receiving an optimally titrated <b>basal</b> insulin (ie, a long-acting insulin such as glargine, degludec, or detemir) as part of their regimen, consider combination injectable therapy (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Combination injectable therapy:</i> If HbA<sub>1c</sub> target has not been met with <b>basal </b>insulin (ie, long-acting insulin such as glargine, degludec or detemir) (usually combined with metformin +/- other noninsulin agent), despite titrating <b>basal</b> insulin to provide acceptable fasting blood glucose concentrations, combination injectable therapy should be considered. Options include: adding a rapid-acting insulin (eg, lispro, aspart, glulisine) prior to largest meal <b>or</b> adding a GLP-1 receptor agonist <b>or</b> changing from <b>basal </b>insulin to a twice daily premixed insulin. If HbA<sub>1c </sub>still not adequately controlled, consider advancing from one rapid-acting insulin prior to largest meal to &lsquo;basal-bolus&rsquo; regimen (ie, rapid-acting insulin administered before &ge;2 meals) <b>or</b> consider advancing from a twice daily premixed insulin to a 3 times daily premixed insulin (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients with </i>\n      <i>elevated HbA<sub>1C</sub> at therapy initiation:</i> If HbA<sub>1c</sub> is &ge;9% at initiation of therapy, dual therapy (metformin + a second antihyperglycemic agent) should be considered. If HbA<sub>1c</sub> &ge;10%, blood glucose is &ge;300 mg/dL or if patient is symptomatic (eg, polyuria, polydipsia), insulin therapy (with or without additional agents) should be considered (ADA 2017f).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2307975\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=insulin-glargine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Insulin glargine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulin glargine is a long-acting insulin administered by SubQ injection. Insulin glargine is approximately equipotent to human insulin, but has a slower onset, no pronounced peak, and a longer duration of activity. Changing the basal insulin component from another insulin to insulin glargine can be done on a unit-to-unit basis. Insulin requirements vary dramatically between patients and dictates frequent monitoring and close medical supervision. See Insulin Regular for additional information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Insulin glargine-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Type 1 diabetes mellitus:</b> Children &ge;6 years and Adolescents: SubQ: Initial dose: Approximately one-third of the total daily insulin requirement; a rapid-acting or short-acting insulin should also be used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Type 1 or type 2 diabetes; previously receiving basal insulin plus bolus insulin (eg, NPH + regular insulin): </b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;6 years: SubQ: Limited data available: 40% of the established total daily insulin requirement; this resulted in a reduction in hypoglycemic episodes in 35 nonobese preschool-aged children (age range: 2.6-6.3 years) when used in conjunction with a rapid-acting insulin prior to meals (Alemzadeh, 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;6 years: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Converting from once-daily NPH insulin: May be substituted on an equivalent unit-per-unit basis</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Converting from twice-daily NPH insulin: Initial dose: Use 80% of the total daily dose of NPH (eg, 20% reduction); administer once daily; adjust dosage according to patient response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General insulin dosing (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Type 1 diabetes mellitus:</b> Children and Adolescents: <b>Note:</b> Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the <b>total units/kg/day of all insulin formulations</b> used. Insulin glargine must be used in combination with a short-acting insulin.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Usual maintenance range:</b> SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Nonobese: 0.4 to 0.6 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Obese: 0.8 to 1.2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and in some cases up to 2 units/kg/day (IDF/ISPAD, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Dosage adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2110692\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114395\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5498540\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20338935\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104245\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lantus: 100 units/mL (10 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Basaglar KwikPen: 100 units/mL (3 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lantus SoloStar: 100 units/mL (3 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Toujeo SoloStar: 300 units/mL (1.5 mL) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114347\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50290219\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage Forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Basaglar: 100 units/mL (cartridge) (3 mL) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2110693\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ administration: Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles. Insulin glargine should be administered once daily, at any time of day; however, administer at the same time each day. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites within the same region to avoid lipodystrophy. Do not dilute or mix insulin glargine with any other insulin formulation or solution. Insulin glargine prefilled pens are available in concentrations of 100 units/mL and 300 units/mL. Prefilled pens are calibrated to display the actual insulin units administered (no dosage conversion needed) and will administer up to 80 units per injection. Do not use a syringe to withdraw concentrated insulin glargine (300 units/mL) from a prefilled pen for administration. Cartridges [Canadian product] are to be used only with re-usable pens recommended by the manufacturer (refer to product labeling).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114351\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, types 1 and 2:</b> To improve glycemic control in adults with type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin, NIDDM); to improve glycemic control in children &ge;6 years with type 1 diabetes mellitus (Lantus and Basaglar only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not recommended for the treatment of diabetic ketoacidosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114344\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Insulin glargine may be confused with insulin glulisine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lantus may be confused with latanoprost, Latuda, Xalatan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b><i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Insulin glargine is a clear solution, but it is NOT intended for IV or IM administration.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lantus [US, Canada, and multiple international markets] may be confused with Lanvis brand name for thioguanine [Canada and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2110684\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Primarily symptoms of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (20%), peripheral edema (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (Type I on combination regimens: &le;69%; Type II on combination regimens: &le;8%; monotherapy in adults &ge;50 years old: 6% [ORIGIN trial])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (20% to 44%; effect on therapy not reported)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (19%), infection (9% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (14%), back pain (13%), limb pain (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Cataract (18%), retinopathy (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (adults: 6% to 29%; children &amp; adolescents: 14%), sinusitis (19%), bronchitis (15%), nasopharyngitis (7% to 13%), cough (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Retinal vascular disease (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (children &amp; adolescents: 8%), rhinitis (children &amp; adolescents: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Sodium retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site, itching at injection site, localized edema, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, bronchospasm, hyperglycemia, hypersensitivity reaction, hypertrophy at injection site, hypokalemia, hypotension, injection site reaction (including urticaria and inflammation), lipoatrophy at injection site, lipoatrophy at injection site, shock, skin rash, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2110683\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to insulin glargine or any component of the formulation; during episodes of hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for insulin is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114356\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe, life-threatening allergic reactions, including anaphylaxis, may occur. If hypersensitivity reactions occur, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine, insulin degludec) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen (insulin regular) in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, <b>basal </b>insulin or <b>basal</b> plus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of <b>basal </b>insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Insulin glargine is a clear solution, but it is <b>NOT</b> intended for IV or IM administration or via an insulin pump.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin), insulin administered via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114383\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114382\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9023&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the hypoglycemic effect of Insulins.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving  both basal insulin and a sulfonylurea.<b> Exceptions: </b>Liraglutide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: If liraglutide is used for the treatment of diabetes (Victoza), consider insulin dose reductions. The combination of liraglutide and insulin should be avoided if liraglutide is used exclusively for weight loss (Saxenda).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114353\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013; Lambert 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28 to 32 weeks' gestation. Following delivery, insulin requirements decrease rapidly (ACOG 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018c). Because insulin glargine has an increased affinity to the insulin-like growth factor (IGF-I) receptor, there are theoretical concerns that it may contribute to adverse events when used during pregnancy (Jovanovic 2007; Lambert 2013), although this has not been observed in available studies (Lambert 2013; Lepercq 2012; Pollex 2011). Women who are stable on insulin glargine prior to conception may continue it during pregnancy. Theoretical concerns of insulin glargine should be discussed prior to conception (Blumer 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2110682\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In a study using insulin glargine, both exogenous and endogenous insulin were present in breast milk (Whitmore 2012). Breastfeeding is encouraged for all women, including those with type 1, type 2, or GDM (ACOG 2005; ADA 2018c; Blumer 2013; Metzger 2007). A small snack (such as milk) before breastfeeding may help decrease the risk of hypoglycemia in women with pregestational diabetes (ACOG 2005; Reader 2004). The manufacturer considers the use of insulin glargine to be compatible with breastfeeding, although adjustments of the mothers insulin dose may be needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8103878\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114396\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Diabetes mellitus: Plasma glucose, electrolytes, HbA<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2017a]), potassium (in patients at risk for hypokalemia); renal function; hepatic function; weight</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114390\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2017a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA1c goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2017b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in pediatric (all age groups) patients with type 1 diabetes (ADA 2017e):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (individualization may be appropriate based on patient-specific characteristics; &lt;7% is reasonable if it can be achieved without excessive hypoglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime and overnight capillary blood glucose: 90 to 150 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for hospitalized adult patients with diabetes (ADA 2017d): Target glucose range: 140 to 180 mg/dL (majority of critically ill and noncritically ill patients; &lt;140 mg/dL may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia). Initiate insulin therapy for persistent hyperglycemia at &ge;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for perioperative care in adult patients with diabetes (ADA 2017d): Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114388\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Insulin glargine differs from human insulin by adding two arginines to the C-terminus of the B-chain in addition to containing glycine at position A21 in comparison to the asparagine found in human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin glargine is a long-acting insulin analog.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114391\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (adsorption and onset of action are more rapid after deeper IM injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Onset of action: Lantus: 3 to 4 hours; Toujeo: 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Lantus, Basaglar: No pronounced peak</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Lantus, Basaglar: Generally 24 hours or longer; reported range (Lantus): 10.8 to &gt;24 hours (up to ~30 hours documented in some studies) (Heinemann 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Slow; upon injection into the subcutaneous tissue, microprecipitates form which allow small amounts of insulin glargine to release over time </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Partially metabolized in the subcutaneous depot at the carboxyl terminus of the B chain to form two active metabolites, M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Lantus: No pronounced peak; Basaglar: ~12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422169\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lantus Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (10 mL): $307.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Basaglar KwikPen Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $78.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Lantus SoloStar Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $92.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Toujeo SoloStar Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 units/mL (1.5 mL): $141.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869463\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abasaglar (DK, EE, ES, GB, HR, LT, NL, NO, PL, PT, SK);</li>\n      <li>Abasria (MT);</li>\n      <li>Basagine (PH);</li>\n      <li>Basaglar (ID, SG);</li>\n      <li>Basaglar KwikPen (PH);</li>\n      <li>Basalin (TH);</li>\n      <li>Basalog (MY);</li>\n      <li>Bonglixan (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Glargilin (PH);</li>\n      <li>Glaritus (PH, VN);</li>\n      <li>Insulet GN (BD);</li>\n      <li>Lantus (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SR, SV, TH, TR, TT, TW, UA, UY, VE, VN, ZW);</li>\n      <li>Lantus XR (JP);</li>\n      <li>Optisulin (CZ, EE, FI, IE, IN, LT, MT, NL, PL, PT, RO);</li>\n      <li>Toujeo (SG);</li>\n      <li>Tozheo (UA);</li>\n      <li>Tuojeo (GB, HK, HR, IE, MY, NL, PH, SK);</li>\n      <li>Vibrenta (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. <i>Pediatrics</i>. 2005;115(5):1320-1324. doi: 10.1542/peds.2004-1439.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/15867042/pubmed\" target=\"_blank\" id=\"15867042\">15867042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG)Committee on Practice Bulletins&mdash;Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/29370047/pubmed\" target=\"_blank\" id=\"29370047\">29370047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979893\"></a>American Diabetes Association (ADA). 6. Glycemic targets. <i>Diabetes Care</i>. 2017a;40(suppl 1):S48&ndash;S56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/27979893/pubmed\" target=\"_blank\" id=\"27979893\">27979893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 11. Older adults. <i>Diabetes Care</i>. 2017b;40(suppl 1):S99&ndash;S104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/27979898/pubmed\" target=\"_blank\" id=\"27979898\">27979898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 12. Children and adolescents. <i>Diabetes Care</i>. 2017e;40(suppl 1):S105&ndash;S113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/27979899/pubmed\" target=\"_blank\" id=\"27979899\">27979899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2018. <i>Diabetes Care</i>. 2018c;41(Suppl 1):S137-S143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 14. Diabetes care in the hospital. <i>Diabetes Care</i>. 2017d;40(suppl 1):S120&ndash;S127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/27979901/pubmed\" target=\"_blank\" id=\"27979901\">27979901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 8. Pharmacologic approaches to glycemic treatment. <i>Diabetes Care.</i> 2017f;40(suppl 1):S64&ndash;S74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/27979895/pubmed\" target=\"_blank\" id=\"27979895\">27979895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basaglar (insulin glargine) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basaglar (insulin glargine). [product monograph]. Scarborough, Ontario, Canada: Eli Lilly Canada Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, &quot;Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,&quot; <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo; <i>Diabetes Care</i>, 2005, 28(6):1282-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/15920040/pubmed\" target=\"_blank\" id=\"15920040\">15920040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garber AJ, Abrahamson MJ, Barzilay JI. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2016 Executive Summary. <i>Endocr Pract</i>. 2016;22(1):84-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/26731084/pubmed\" target=\"_blank\" id=\"26731084\">26731084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerstein HC, Yale JF, Harrist SB, et al, &ldquo;A Randomized Trial of Adding Insulin Glargine Vs. Avoidance of Insulin in People with Type 2 Diabetes on Either No Oral Glucose-Lowering Agents or Submaximal Doses of Metformin and/or Sulphonylureas: The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,&rdquo; <i>Diabet Med</i>, 2006, 23(7):736-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/16842477/pubmed\" target=\"_blank\" id=\"16842477\">16842477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamann A, Matthaei S, Rosack C, et al, &ldquo;A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes,&rdquo; <i>Diabetes Care</i>, 2003, 26(6):1738-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/12766103/pubmed\" target=\"_blank\" id=\"12766103\">12766103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinemann L, Hompesch B, Linkeschova R, et al, &ldquo;Time-Action Profile of the Long-Acting Insulin Analog Insulin Glargine (HOE901) in Comparison With Those of NPH and Placebo,&rdquo; <i>Diabetes Care</i>, 2000, 23(5):644-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/10834424/pubmed\" target=\"_blank\" id=\"10834424\">10834424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holman RR, Thorne KI, Farmer AJ, et al, &ldquo;Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes,&rdquo; <i>N Engl J Med</i>, 2007, 357(17):1716-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/17890232/pubmed\" target=\"_blank\" id=\"17890232\">17890232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Diabetes Federation, International Society for Pediatric and Adolescent Diabetes. Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. 2011. Available at http://www.idf.org/global-idfispad-guideline-diabetes-childhood-and-adolescence. Last accessed: October 21, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jovanovic L, Pettitt DJ. Treatment with insulin and its analogs in pregnancies complicated by diabetes. <i>Diabetes Care</i>. 2007;30(Suppl 2):S220-224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/17596476 /pubmed\" target=\"_blank\" id=\"17596476 \">17596476 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert K, Holt RI. The use of insulin analogues in pregnancy.<i> Diabetes Obes Metab</i>. 2013;15(10):888-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/23489521 /pubmed\" target=\"_blank\" id=\"23489521 \">23489521 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lantus (insulin glargine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lantus (insulin glargine) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepercq J , Lin J, Hall GC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. <i>Obstet Gynecol Int</i> . 2012;2012:649070.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/22685467/pubmed\" target=\"_blank\" id=\"22685467\">22685467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepore M, Pampanelli S, Fanelli C, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of Long-Acting Human Insulin Analog Glargine, NPH Insulin, and Ultralente Human Insulin and Continuous Subcutaneous Infusion of Insulin Lispro,&rdquo; <i>Diabetes</i>, 2000, 49(12):2142-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/11118018/pubmed\" target=\"_blank\" id=\"11118018\">11118018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy,&rdquo; <i>Diabetes Care</i>, 2009, 32(1):193-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/18945920/pubmed\" target=\"_blank\" id=\"18945920\">18945920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Owens DR, Coates PA, Luzio SD, et al, &ldquo;Pharmacokinetics of 125I-Labeled Insulin Glargine (HOE 901) in Healthy Men,&rdquo; <i>Diabetes Care</i>, 2000, 23(6):813-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/10841002/pubmed\" target=\"_blank\" id=\"10841002\">10841002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollex E, Moretti ME, Koren G, Feig DS. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. <i>Ann Pharmacother</i> . 2011;45(1):9-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/21205954/pubmed\" target=\"_blank\" id=\"21205954\">21205954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Porcellati F, Rossetti P, Ricci NB, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes,&rdquo; <i>Diabetes Care</i>, 2007, 30(5):1261-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/17303785/pubmed\" target=\"_blank\" id=\"17303785\">17303785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo; <i>Ann Intern Med</i>, 2012, 156(3):218-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/22312141/pubmed\" target=\"_blank\" id=\"22312141\">22312141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raskin P, Klaff L, Bergenstal R, et al, &ldquo;A 16-Week Comparison of the Novel Insulin Analog Insulin Glargine (HOE901) and NPH Human Insulin Used With Insulin Lispro in Patients With Type 1 Diabetes,&rdquo; <i>Diabetes Care</i>, 2000, 23(11):1666-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/11092290/pubmed\" target=\"_blank\" id=\"11092290\">11092290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ratner RE, Hirsch IB, Neifing JL, et al, &ldquo;Less Hypoglycemia With Insulin Glargine in Intensive Insulin Therapy for Type 1 Diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes,&rdquo; <i>Diabetes Care</i>, 2000, 23(5):639-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/10834423/pubmed\" target=\"_blank\" id=\"10834423\">10834423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/15461903 /pubmed\" target=\"_blank\" id=\"15461903 \">15461903 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MC, Rosenstock J, and Gerich J, &ldquo;The Treat-To-Target Trial,&rdquo; <i>Diabetes Care</i>, 2003, 26(11):3080-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/14578243/pubmed\" target=\"_blank\" id=\"14578243\">14578243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenstock J, Schwartz SL, Clark CM Jr, et al, &ldquo;Basal Insulin Therapy in Type 2 Diabetes,&rdquo; <i>Diabetes Care</i>, 2001, 24(4):631-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/11315821/pubmed\" target=\"_blank\" id=\"11315821\">11315821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schober E, Schoenle E, Van Dyk J, et al, &ldquo;Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents With Type 1 Diabetes,&rdquo; <i>Diabetes Care</i>, 2001, 24(11):2005-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/11679478/pubmed\" target=\"_blank\" id=\"11679478\">11679478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scholtz HE, Pretorius SG, Wessels DH, et al, &ldquo;Pharmacokinetic and Glucodynamic Variability: Assessment of Insulin Glargine, NPH Insulin, and Insulin Ultralente in Healthy Volunteers Using a Euglycaemic Clamp Technique,&rdquo; <i>Diabetologia</i>, 2005, 48(10):1988-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/16160867/pubmed\" target=\"_blank\" id=\"16160867\">16160867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo; <i>Diabetes Care,</i> 2005, 28(1):186-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/15616254/pubmed\" target=\"_blank\" id=\"15616254\">15616254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toujeo (insulin glargine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/22500167 /pubmed\" target=\"_blank\" id=\"22500167 \">22500167 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yki-Jarvinen H, Dressler A, and Ziemen M, &ldquo;Less Nocturnal Hypoglycemia and Better Post-Dinner Glucose Control With Bedtime Insulin Glargine Compared With Bedtime NPH Insulin During Insulin Combination Therapy in Type 2 Diabetes,&rdquo; <i>Diabetes Care</i>, 2000, 23(8):1130-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glargine-drug-information/abstract-text/10937510/pubmed\" target=\"_blank\" id=\"10937510\">10937510</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9023 Version 176.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50707937\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2114346\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2186124\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2114349\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2110691\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2307975\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2110692\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2114395\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5498540\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20338935\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2104245\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2114347\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50290219\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2110693\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2114351\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2114344\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2110684\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2110683\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2114356\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F2114383\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2114382\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2114353\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2110682\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8103878\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2114396\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F2114390\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2114388\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2114391\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422169\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869463\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9023|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=insulin-glargine-patient-drug-information\" class=\"drug drug_patient\">Insulin glargine: Patient drug information \t</a></li><li><a href=\"topic.htm?path=insulin-glargine-pediatric-drug-information\" class=\"drug drug_pediatric\">Insulin glargine: Pediatric drug information</a></li></ul></div></div>","javascript":null}